A Study to Investigate Safety and Tolerability of NDX-3315 and NDX-3324 in Healthy Participants and Patients With Eosinophilic Esophagitis
Key facts
- Who runs it
- NexEos Diagnostics, Inc.
- Where
- Chicago, Philadelphia, and Salt Lake City, United StatesSee the 3 sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 34 people enrolled
- Started
- 20 Jan 2023
- Ended
- 22 May 2025
- Type of study
- Interventional, 2 groups
- Treatments tested
- NDX-3315
- NDX-3324
- SPECT/CT Imaging
- Record updated
- 14 May 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Healthy Participants:; Participants who are healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and electrocardiogram (ECG) assessment
- EoE Participants:; Documented diagnosis of EoE (based on prior endoscopy with biopsies showing eosinophils ≥15 / HPF); AND; History (by patient report) of recurrent dysphagia and/or other related EoE symptoms (with intake of solids off anti-inflammatory therapy) prior to screening; dysphagia is defined as trouble swallowing solid food, or having solid food stuck, by patient report
Who cannot take part
- Prior/Concomitant Therapy:; Participant who is on anticoagulation therapy that, in the investigator or Medical Monitor's opinion, cannot safely come off medication; Use of chronic aspirin (with the exception of low-dose aspirin as long as the dose remains stable and not increased while on study), nonsteroidal agents, or anti-coagulants within 2 weeks prior to screening; Use of systemic corticosteroids within 3 months or swallowed topical corticosteroids within 6 weeks prior to Screening visit; Participant is being treated with systemic immunosuppression, carafate (sucralfate), or investigational agent of any kind within less than 3 months or 5 half-lives, whichever is longer, prior to Screening visit (this also includes investigational formulations of marketed products)
- Medical Conditions:; Participant with presence of any other disease of the GI tract, including cancer, autoimmune esophageal disease, GERD which is symptomatic or uncontrolled, Barrett's esophagus, eosinophilic gastritis, enteritis, colitis, or proctitis; inflammatory bowel disease; or celiac disease. Known motility disorder of esophagus; achalasia or suspicion thereof; Sleep apnea, if considered by the investigator a concern for the endoscopic procedure; History of recurrent aspiration pneumonia; History of bleeding disorders, liver cirrhosis or esophageal varices; A current malignancy or previous history of cancer in remission for less than 5 years prior to Screening (participants will not be excluded if they had localized carcinoma of the skin that was resected for cure); Participant with a Body Mass Index >40 m2/kg or inability to undergo a CT (or SPECT scan) due to weight limitations; Participant is pregnant or nursing
- Diagnostic Assessments:; Evidence of clinically significant abnormality in the hematological and biochemical assessments at Screening Visit, specifically: International Normalized Ratio (INR) >1.4; platelet count <80,000/μL and creatinine level >2 mg/dL; ECG: QTcF ≥450 msec for males and QTcF ≥470 msec for females at the time of screening
- Other Exclusion Criteria:; Any condition that would not permit adequate biopsies of the esophagus (e.g., esophageal varices, significant stricture precluding passage of a 9 mm endoscope, known allergy to sedative used for endoscopy); Healthy Participants Only: A history or current diagnosis of allergic diseases (Should be discussed with Medical Monitor and PI to decide whether exclusionary), autoimmune disease, chronic rhinosinusitis or serum immunoglobulin E (IgE) level ≥100 kU/L. On any medications including NSAIDS and any over the counter (OTC) medications unless it is birth control or acne medications with the exception of Accutane, or if deemed acceptable to use by Medical Monitor and PI
Where in United States
- Northwestern UniverisityChicago, United States
- University of PennsylvaniaPhiladelphia, United States
- University of UtahSalt Lake City, United States
About the trial
What the trial wants to find out
An open-label phase 2 study to assess the safety and exploratory diagnostic performance of the oral radiopharmaceutical agent NDX-3315 and NDX-3324 in healthy participants and patients with eosinophilic esophagitis (EoE).
The 2 groups in the trial
- Participants Receiving NDX-3315Treatment being tested
Participants receive NDX-3315 (delivered via oral syringe at \~ 1.5 mL per minute) using Regimen 5 (5 sips administered over approximately 5 minutes) or Regimen 10 (10 sips administered over approximately 10 minutes), followed by SPECT/CT imaging. Both healthy participants and participants with EoE are included.
Treatment: NDX-3315 and SPECT/CT Imaging
- Participants Receiving NDX-3324Treatment being tested
Participants receive NDX-3324 (delivered via oral syringe at \~ 1.5 mL per minute) using Regimen 10 (10 sips administered over approximately 10 minutes) in a sitting reclined position, followed by SPECT/CT imaging. Both healthy participants and participants with EoE are included.
Treatment: NDX-3324 and SPECT/CT Imaging
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Open-label Phase 2 Study Assessing the Safety, Tolerability and Preliminary Diagnostic Performance of a Radioactive Imaging Agent, NDX-3315 and NDX-3324, in Healthy Adult Participants and Patients With Eosinophilic Esophagitis
- Record updated
- 14 May 2026